Navin K. Chintala

2.3k total citations · 1 hit paper
24 papers, 1.3k citations indexed

About

Navin K. Chintala is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Navin K. Chintala has authored 24 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 7 papers in Immunology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Navin K. Chintala's work include CAR-T cell therapy research (17 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Immunotherapy and Immune Responses (4 papers). Navin K. Chintala is often cited by papers focused on CAR-T cell therapy research (17 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Immunotherapy and Immune Responses (4 papers). Navin K. Chintala collaborates with scholars based in United States, China and Australia. Navin K. Chintala's co-authors include Prasad S. Adusumilli, Rachel Grosser, Leonid Cherkassky, Surya Kumari Vadrevu, Sharad Sharma, Maciej M. Markiewski, Magdalena Karbowniczek, Zachary E. Tano, David P. Fairlie and Xiaoyu Li and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer Cell.

In The Last Decade

Navin K. Chintala

23 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

2019 405 citations Rachel Grosser, Leonid Cherkassky et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Navin K. Chintala United States	13	850	620	365	255	186	24	1.3k
Bianca Altvater Germany	24	993 1.2×	736 1.2×	355 1.0×	183 0.7×	249 1.3×	44	1.4k
Liang-Chuan Wang United States	7	677 0.8×	372 0.6×	226 0.6×	228 0.9×	83 0.4×	14	867
Sherly Mardiana Australia	12	1.2k 1.4×	824 1.3×	444 1.2×	306 1.2×	76 0.4×	13	1.5k
Kevin Sek Australia	8	935 1.1×	749 1.2×	419 1.1×	205 0.8×	77 0.4×	11	1.3k
Junyun Lai Australia	13	819 1.0×	697 1.1×	336 0.9×	182 0.7×	67 0.4×	16	1.2k
Nicholas G. Minutolo United States	7	512 0.6×	559 0.9×	321 0.9×	207 0.8×	96 0.5×	9	955
Konstantin Dobrenkov United States	15	559 0.7×	363 0.6×	235 0.6×	131 0.5×	68 0.4×	28	829
Sylvia M. Lee United States	13	986 1.2×	733 1.2×	328 0.9×	110 0.4×	149 0.8×	19	1.3k
Sareetha Kailayangiri Germany	16	718 0.8×	524 0.8×	272 0.7×	124 0.5×	192 1.0×	29	1.0k
Xiaojun Qian China	9	1.3k 1.5×	521 0.8×	392 1.1×	353 1.4×	91 0.5×	22	1.5k

Countries citing papers authored by Navin K. Chintala

Since Specialization

Citations

This map shows the geographic impact of Navin K. Chintala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Navin K. Chintala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Navin K. Chintala more than expected).

Fields of papers citing papers by Navin K. Chintala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Navin K. Chintala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Navin K. Chintala. The network helps show where Navin K. Chintala may publish in the future.

Co-authorship network of co-authors of Navin K. Chintala

This figure shows the co-authorship network connecting the top 25 collaborators of Navin K. Chintala. A scholar is included among the top collaborators of Navin K. Chintala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Navin K. Chintala. Navin K. Chintala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chintala, Navin K., et al.. (2024). Abstract 3993: A tunable safety switch for solid tumor CAR T-cell therapy. Cancer Research. 84(6_Supplement). 3993–3993. 1 indexed citations

Xiong, Yuquan, Zhaohua Hou, Srijita Banerjee, et al.. (2023). c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation. Nature Cancer. 4(7). 1001–1015. 10 indexed citations

Chintala, Navin K., Erin McGee, Srijita Banerjee, et al.. (2023). Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma. Frontiers in Immunology. 14. 1112960–1112960. 16 indexed citations

Restle, David, Xiaoyu Li, Yan Li, et al.. (2023). Organ-specific heterogeneity in tumor-infiltrating immune cells and cancer antigen expression in primary and autologous metastatic lung adenocarcinoma. Journal for ImmunoTherapy of Cancer. 11(6). e006609–e006609. 12 indexed citations

Tano, Zachary E., et al.. (2023). Ex vivo pleural effusion cultures to study chimeric antigen receptor T cell cytotoxicity in an immunocompetent environment. Cell Reports Methods. 3(11). 100622–100622.

Gross, Daniel, Navin K. Chintala, Rachel Grosser, et al.. (2021). Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma. Journal of Thoracic Oncology. 17(1). 89–102. 23 indexed citations

Chintala, Navin K., et al.. (2021). CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials. Lung Cancer. 157. 48–59. 23 indexed citations

Chintala, Navin K., et al.. (2021). Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity. Nature Protocols. 16(3). 1331–1342. 71 indexed citations

Adusumilli, Prasad S., Navin K. Chintala, Zhaohua Hou, et al.. (2021). 46MO Promoting functional persistence in solid tumor CAR T-cell therapy: Mesothelin-targeted CAR (M28z1XXPD1DNR) with T-cell intrinsic PD1 dominant negative receptor. Annals of Oncology. 32. S1392–S1393. 2 indexed citations

10.

Adusumilli, Prasad S., Marjorie G. Zauderer, Valerie W. Rusch, et al.. (2019). Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy. Cancer Research. 79(13_Supplement). CT036–CT036. 44 indexed citations

11.

Li, Xiaoyu, Takashi Eguchi, Rania G. Aly, et al.. (2019). Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy. Frontiers in Oncology. 9. 1042–1042. 9 indexed citations

12.

Grosser, Rachel, Leonid Cherkassky, Navin K. Chintala, & Prasad S. Adusumilli. (2019). Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. Cancer Cell. 36(5). 471–482. 405 indexed citations breakdown →

13.

Adusumilli, Prasad S., Marjorie G. Zauderer, Valerie W. Rusch, et al.. (2019). Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy. Clinical Trials. CT036–CT036. 8 indexed citations

14.

Chintala, Navin K., et al.. (2018). MA11.01 Comparative Efficacy of T-Cell Intrinsic Versus Extrinsic PD-1 Blockade to Overcome PD-L1+ Tumor-Mediated Exhaustion. Journal of Thoracic Oncology. 13(10). S392–S392. 4 indexed citations

15.

Tano, Zachary E., et al.. (2018). MA06.06 An Ex-Vivo Patient-Derived, Immunocompetent (PDI) Culture System to Evaluate Immunotherapeutic Agents’ Anti-Tumor Efficacy. Journal of Thoracic Oncology. 13(10). S376–S376. 3 indexed citations

16.

Chen, Nan, Xiaoyu Li, Navin K. Chintala, Zachary E. Tano, & Prasad S. Adusumilli. (2018). Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Current Opinion in Immunology. 51. 103–110. 101 indexed citations

17.

Chicaybam, Leonardo, et al.. (2017). Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies. Journal of Thoracic Oncology. 13(1). 16–26. 71 indexed citations

18.

Tano, Zachary E., Navin K. Chintala, Xiaoyu Li, & Prasad S. Adusumilli. (2017). Novel immunotherapy clinical trials in malignant pleural mesothelioma. Annals of Translational Medicine. 5(11). 245–245. 4 indexed citations

19.

Vadrevu, Surya Kumari, et al.. (2016). Studying the Role of Alveolar Macrophages in Breast Cancer Metastasis. Journal of Visualized Experiments. 6 indexed citations

20.

Vadrevu, Surya Kumari, Navin K. Chintala, Sharad Sharma, et al.. (2014). Complement C5a Receptor Facilitates Cancer Metastasis by Altering T-Cell Responses in the Metastatic Niche. Cancer Research. 74(13). 3454–3465. 161 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact